-
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
(PAR-19-328)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): New and Revision Applications: October 11, 2019, February 11, 2020, June 10, 2020, October 14, 2020, February 11, 2021, June 10, 2021, October 14, 2021, February 11, 2022, June 10, 2022 by 5:00 PM local time of applicant organization.
Resubmission Applications: November 12, 2019, March 11, 2020, July 10, 2020, November 17, 2020, March 11, 2021, July 13, 2021, November 15, 2021, March 11, 2022, July 11, 2022 by 5:00 PM local time of applicant organization.
All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
(PAR-19-329)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): New and Revision Applications: October 11, 2019, February 11, 2020, June 10, 2020, October 14, 2020, February 11, 2021, June 10, 2021, October 14, 2021, February 11, 2022, June 10, 2022 by 5:00 PM local time of applicant organization.
Resubmission Applications: November 12, 2019, March 11, 2020, July 10, 2020, November 17, 2020, March 11, 2021, July 13, 2021, November 15, 2021, March 11, 2022, July 11, 2022 by 5:00 PM local time of applicant organization.
All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applications must be submitted for the same due date as the collaborating DCC application.
-
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
(PAR-19-330)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): New and Revision Applications: October 11, 2019, February 11, 2020, June 10, 2020, October 14, 2020, February 11, 2021, June 10, 2021, October 14, 2021, February 11, 2022, June 10, 2022 by 5:00 PM local time of applicant organization.
Resubmission Applications: November 12, 2019, March 11, 2020, July 10, 2020, November 17, 2020, March 11, 2021, July 13, 2021, November 15, 2021, March 11, 2022, July 11, 2022 by 5:00 PM local time of applicant organization.
Applications must be submitted for the same due date as the collaborating CCC (UG3/UH3) application.
-
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed
(PAR-19-333)
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of General Medical Sciences
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply
All applications are due by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, R44) Clinical Trial Not Allowed
(PAR-19-334)
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of General Medical Sciences
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Center for Advancing Translational Sciences
National Institute of Biomedical Imaging and Bioengineering
National Center for Advancing Translational Sciences
Application Receipt Date(s): Standard dates apply
All applications are due by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Required
(PAR-19-335)
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Deafness and Other Communication Disorders
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply
All applications are due by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)
(PAR-19-337)
National Center for Advancing Translational Sciences
National Center for Advancing Translational Sciences
Application Receipt Date(s): September 25, 2019, September 25, 2020, September 27, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Limited Competition: Renewals of, and Revisions and Resubmissions to, the Longitudinal Early-onset Alzheimers Disease Study (LEADS) Cooperative Agreement (U01 Clinical Trial Not Allowed)
(PAR-19-338)
National Institute on Aging
Application Receipt Date(s): Standard dates apply
-
The Biological Mechanisms of Metformin Effects on Aging and Longevity (R01 Clinical Trial Not Allowed)
(RFA-AG-20-044)
National Institute on Aging
Application Receipt Date(s): January 21, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
No late applications will be accepted for this funding opportunity announcement.
-
Technologies to Advance Precision Medicine Diagnosis and Treatment of Infertility, Reproductive Tract and Gynecologic Disorders Affecting Fertility (R43/R44 Clinical Trial Optional)
(RFA-HD-20-010)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): December 3, 2019
-
Circadian Patterns of Gene Expression Associated with Disease (R01 - Clinical Trial Optional)
(RFA-HL-20-016)
National Heart, Lung, and Blood Institute
National Institute on Drug Abuse
Application Receipt Date(s): October 7, 2019